Colorectal Cancer

Combining interventions to encourage screenings for colorectal cancer (CRC) and social determinants of health (SDOH) was found to improve screening rates in CRC without decreasing rates of screenings for SDOH.

Emergent colorectal cancer (CRC) resection was found to be more prevalent in patients who identified as non-White.

Several risk factors put patients with colorectal cancer at increased risk of anastomotic leakage after elective surgery.

Patients with colorectal cancer (CRC) could participate in telehealth and e-health interventions to promote their sexual health, although efficacy of these interventions needs to be further studied.

Obesity related to metabolic syndrome was found to have a causal relationship with colorectal cancer (CRC), although this causal relationship did not exist in the opposite direction.

Incidence of colorectal cancer is expected to rise in both male and female patients aged 50 years and younger.

Mortality and morbidity in patients with colorectal cancer (CRC) cannot be accurately predicted using the Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity (POSSUM) in the present day.

Patients with chronic kidney disease are at a higher risk of developing any stage of colorectal cancer.

Patients with colorectal cancer (CRC) undergoing operations were able to prevent postoperative infections and shorten hospital stays by taking probiotics beforehand.

Tumor grading via least differentiation analysis was found to be a way to measure the risk of lymph node metastasis (LNM) in patients with submucosal invasive colorectal cancer (CRC).

The topics included clinical staging of colorectal cancer, FDA approvals, and a study published in the print version of the American Journal of Managed Care®.

Patients with colorectal cancer (CRC) had reduced readmissions when treatment focused on preventing prolonged ileus, increasing the use of minimally invasive surgery, and preventing anastomotic leaks.

Patients aged 80 years and older with colorectal cancer (CRC) could have an improved prognosis at the completion of adjuvant chemotherapy.

Skeletal muscle proved to be significant in calculating chemotherapy toxicities in nonmetastatic colorectal cancer (CRC).

Patients with metastatic colorectal cancer (CRC) who experience colon perforation may have similar survival times to those without perforation.

Predicting clinical outcomes in patients with colorectal cancer (CRC) could be done using the novel comprehensive blood indicator PSI.

Although the incidence of colorectal cancer (CRC) decreased in individuals older than 50 years, incidence of CRC increased in male individuals younger than 50 years.

A Mendelian randomization found that a potential link between constipation and colorectal cancer, with support for constipation as a cause of colorectal cancer.

Patients with colorectal cancer (CRC) who had diagnosed metachronous metastasis had longer overall survival when the primary tumor was detected through screening.

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples.

Critically ill older patients with colorectal cancer (CRC) had their 28-day mortality predicted using machine learning algorithms.

The implementation of a mailed stool test program increased colorectal cancer (CRC) screen-up-to-date rates compared with lower-intensity interventions, such as patient letters.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Caecal cancer and ascending colon cancer had slower rates of metastasis to main nodes compared with transverse colon cancer.

Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage 1 to 4 resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.

Patients with colorectal cancer (CRC) can use C-reactive protein (CRP), lymphocyte to CRP ratio, and CRP to albumin ratio as markers for CRC prognosis.

Patients who underwent surgery for colorectal cancer had a higher risk of postoperative infection if they had high body mass index (BMI) or diabetes, among other risk factors.

The incidence of colorectal serrated lesions could be attributed to metabolic syndrome, which causes metabolic dysregulation.

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.

Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.